Mostrar el registro sencillo del ítem

Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram

dc.creatorLeyva-Gomez, G.
dc.creatorGonzalez-Trujano, M. E.
dc.creatorLopez-Ruiz, E.
dc.creatorCouraud, P. O.
dc.creatorWekslerg, B.
dc.creatorRomero, I.
dc.creatorMiller, F.
dc.creatorDelie, F.
dc.creatorAllemann, E.
dc.creatorQuintanar-Guerrero, D.
dc.date.accessioned2017-06-29T04:00:50Z
dc.date.available2017-06-29T04:00:50Z
dc.date.issued2014es_ES
dc.identifier2841es_ES
dc.identifier.issn0022-3549es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/4690
dc.identifier.urihttps://doi.org/10.1002/jps.24044es_ES
dc.identifier.uri
dc.language.isoenges_ES
dc.publisherNew York, NY : Elsevieres_ES
dc.relation103 (8) 2509-2519 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleNanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogrames_ES
dc.typeartículoes_ES
dc.contributor.affiliationLaboratorio de Investigación y Posgrado en Tecnología Farmacéutica, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de Méxicoes_ES
dc.contributor.emailevag@imp.edu.mxes_ES
dc.relation.jnabreviadoJ PHARM SCIes_ES
dc.relation.journalJournal of Pharmaceutical Scienceses_ES
dc.identifier.placeEstados Unidoses_ES
dc.date.published2014es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn1520-6017es_ES
dc.identifier.doi10.1002/jps.24044.es_ES
dc.description.monthAgoes_ES
dc.description.abstractotrodiomaTo document the efficacy of clonazepam (CLZ) either free as a solution or loaded in solid lipid nanoparticles (CLZ-SLN) or mixed micelles (CLZ-MM), the in vitro blood-brain barrier permeability of the formulations was determined. Behavior and/or electroencephalograms (EEGs) of rodents receiving treatments were also studied. The in vitro permeability of CLZ increased when associated with SLN, but decreased in the case of MM. The occurrence of the pentylenetetrazole (PTZ)-induced seizures in mice was significantly prevented by CLZ, even when exposed a lower dose of CLZ-SLN after administration by the oral route. The behavioral severity and EEGs showing the PTZ-induced paroxystic activity in rats diminished significantly in the presence of CLZ alone (0.3 mg/kg), and were almost totally prevented in the rats treated with CLZ-SLN (equivalent to 0.3 mg/kg). The frequency, duration, and spreading of the spikes-wave of rats treated with CLZ-SLN decreased significantly as compared with CLZ alone, CLZ-MM, or the vehicle. These results show an in vitro-in vivo correlation in the enhanced blood-brain barrier permeability of SLN formulation, and a contribution of MM to the carrier effect of drugs toward the bloodstream and brain, where this pharmaceutical formulation of CLZ-SLN improves the anticonvulsant effect of this benzodiazepine, thus offering additional advantages after oral administration.es_ES
dc.subject.koCNSes_ES
dc.subject.koAbsorption Enhanceres_ES
dc.subject.koAnticonvulsantes_ES
dc.subject.koClonazepames_ES
dc.subject.koDrug Transportes_ES
dc.subject.koElectroencephalogrames_ES
dc.subject.koLipidses_ES
dc.subject.koMicelleses_ES
dc.subject.koPentylenetetrazolees_ES
dc.subject.koSolid Lipid Nanoparticleses_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem